Enliven Therapeutics, Inc. ELVN

ELVN Company Overview

Enliven Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of small molecule precision therapies for cancer. The company primarily operates within the oncology and targeted therapeutics sectors, with an emphasis on kinase inhibition technologies designed to address unmet needs in hematologic malignancies and solid tumors. Enliven’s lead programs are centered on next-generation kinase inhibitors intended to improve tolerability, selectivity, and resistance profiles relative to existing therapies. The company trades publicly on the Nasdaq under the ticker ELVN.

The company’s primary value drivers are its investigational oncology pipeline assets, particularly programs targeting BCR-ABL and HER2 mutations. Its lead candidates include ELVN-001, a selective BCR-ABL inhibitor being evaluated for chronic myeloid leukemia (CML), and ELVN-002, an irreversible HER2 inhibitor being studied in HER2-driven cancers, including central nervous system metastatic disease. Enliven was founded in 2019 by executives and scientists with prior experience in oncology drug development, including leadership backgrounds connected to precision medicine and kinase inhibitor programs. The company has positioned itself around rational drug design and differentiated safety profiles intended to support long-term treatment use in oncology patients.